(Q47855427)

6 February 2018

review article

1 reference

title

Enzyme therapy for Gaucher disease: the first 5 years. (English)

1 reference

6 February 2018

1 reference

G A Grabowski

1

1 reference

6 February 2018

N Leslie

series ordinal

2

1 reference

6 February 2018

R Wenstrup

series ordinal

3

1 reference

6 February 2018

publication date

1 June 1998

1 reference

6 February 2018

published in

Blood Reviews

1 reference

6 February 2018

volume

12

1 reference

6 February 2018

issue

2

1 reference

6 February 2018

page(s)

115-133

1 reference

6 February 2018

METABOLISM OF GLUCOCEREBROSIDES. II. EVIDENCE OF AN ENZYMATIC DEFICIENCY IN GAUCHER'S DISEASE.

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2898%2990023-6

7 January 2021

Glycosphingolipid studies of visceral tissues and brain from type 1 Gaucher disease variants

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2898%2990023-6

7 January 2021

The bilayer nature of deposits occurring in Gaucher's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2898%2990023-6

7 January 2021

Gaucher's disease: molecular, genetic and enzymological aspects

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2898%2990023-6

7 January 2021

Gaucher disease: gene frequencies and genotype/phenotype correlations

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2898%2990023-6

7 January 2021

Biosynthesis and maturation of glucocerebrosidase in Gaucher fibroblasts

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2898%2990023-6

7 January 2021

Characterization of beta-glucosidase as a peripheral enzyme of lysosomal membranes from mouse liver and purification

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2898%2990023-6

7 January 2021

Immunochemical characterization of two activator proteins stimulating enzymic sphingomyelin degradation in vitro. Absence of one of them in a human Gaucher disease variant

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2898%2990023-6

7 January 2021

Activator protein deficient Gaucher's disease. A second patient with the newly identified lipid storage disorder

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2898%2990023-6

7 January 2021

Turnover and distribution of intravenously administered mannose-terminated human acid beta-glucosidase in murine and human tissues.

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2898%2990023-6

7 January 2021

Molecular characterization of the human macrophage mannose receptor: demonstration of multiple carbohydrate recognition-like domains and phagocytosis of yeasts in Cos-1 cells

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2898%2990023-6

7 January 2021

Sequences outside the homeodomain of bicoid are required for protein-protein interaction

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2898%2990023-6

7 January 2021

Mechanism of Ca2+ and monosaccharide binding to a C-type carbohydrate-recognition domain of the macrophage mannose receptor

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2898%2990023-6

7 January 2021

Delayed activation of the mannose receptor following synthesis. Requirement for exit from the endoplasmic reticulum

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2898%2990023-6

7 January 2021

Hepatic sinusoidal endothelium heterogeneity with respect to mannose receptor activity is interleukin-1 dependent

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2898%2990023-6

7 January 2021

An electron microscope autoradiographic study of the carbohydrate recognition systems in rat liver. I. Distribution of 125I-ligands among the liver cell types

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2898%2990023-6

7 January 2021

An electron microscope autoradiographic study of the carbohydrate recognition systems in rat liver. II. Intracellular fates of the 125I-ligands

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2898%2990023-6

7 January 2021

Human beta-glucuronidase: in vivo clearance and in vitro uptake by a glycoprotein recognition system on reticuloendothelial cells

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2898%2990023-6

7 January 2021

Uptake and distribution of placental glucocerebrosidase in rat hepatic cells and effects of sequential deglycosylation

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2898%2990023-6

7 January 2021

The uptake of native and desialylated glucocerebrosidase by rat hepatocytes and Kupffer cells

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2898%2990023-6

7 January 2021

Studies on the turnover of exogenous mannose-terminal glucocerebrosidase in rat liver lysosomes.

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2898%2990023-6

7 January 2021

Rat liver endothelial cells have a greater capacity than Kupffer cells to endocytose N-acetylglucosamine- and mannose-terminated glycoproteins

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2898%2990023-6

7 January 2021

Immunoelectron microscopic localization of mannose-terminal glucocerebrosidase in lysosomes of rat liver Kupffer cells.

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2898%2990023-6

7 January 2021

A biochemical and immunocytochemical study on the targeting of alglucerase in murine liver

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2898%2990023-6

7 January 2021

Therapeutic delivery of proteins to macrophages: implications for treatment of Gaucher's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2898%2990023-6

7 January 2021

Binding, internalization, and degradation of mannose-terminated glucocerebrosidase by macrophages

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2898%2990023-6

7 January 2021

Enzyme Augmentation in Moderate to Life-Threatening Gaucher Disease

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2898%2990023-6

7 January 2021

Enzyme therapy in type 1 Gaucher disease: comparative efficacy of mannose-terminated glucocerebrosidase from natural and recombinant sources

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2898%2990023-6

7 January 2021

A less costly regimen of alglucerase to treat Gaucher's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2898%2990023-6

7 January 2021

Replacement therapy with imiglucerase for type 1 Gaucher's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2898%2990023-6

7 January 2021

Low-dose enzyme replacement therapy for Gaucher's disease: effects of age, sex, genotype, and clinical features on response to treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2898%2990023-6

7 January 2021

Individualised low-dose alglucerase therapy for type 1 Gaucher's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2898%2990023-6

7 January 2021

Replacement therapy for inherited enzyme deficiency--macrophage-targeted glucocerebrosidase for Gaucher's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2898%2990023-6

7 January 2021

Resting energy expenditure in Gaucher's disease type 1: effect of Gaucher's cell burden on energy requirements

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2898%2990023-6

7 January 2021

Skeletal complications of Gaucher disease

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2898%2990023-6

7 January 2021

Gaucher's disease type 1: assessment of bone involvement by CT and scintigraphy

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2898%2990023-6

7 January 2021

Chronic Gaucher's disease: radiological findings in 17 South African cases

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2898%2990023-6

7 January 2021

Skeletal complications of type I Gaucher disease: the magnetic resonance features

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2898%2990023-6

7 January 2021

Pro-inflammatory cytokines and the pathogenesis of Gaucher's disease: increased release of interleukin-6 and interleukin-10.

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2898%2990023-6

7 January 2021

Selective effects of glucocerebroside (Gaucher's storage material) on macrophage cultures

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2898%2990023-6

7 January 2021

A novel splicing abnormality in a Japanese patient with Gaucher's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2898%2990023-6

7 January 2021

Bone density in Type 1 Gaucher disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2898%2990023-6

7 January 2021

Tumour induced hypercalcaemia: a case for active treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2898%2990023-6

7 January 2021

Effects of two oral doses of alendronate in the treatment of Paget's disease of bone

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2898%2990023-6

7 January 2021

Biochemical and radiologic improvement in Paget's disease of bone treated with alendronate: A randomized, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2898%2990023-6

7 January 2021

Alendronate treatment of the postmenopausal osteoporotic woman: effect of multiple dosages on bone mass and bone remodeling

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2898%2990023-6

7 January 2021

Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2898%2990023-6

7 January 2021

Femoral neck fractures complicating Gaucher disease in children

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2898%2990023-6

7 January 2021

Acceleration of retarded growth in children with Gaucher disease after treatment with alglucerase.

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2898%2990023-6

7 January 2021

Low-dose high-frequency enzyme replacement therapy for very young children with severe Gaucher disease

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2898%2990023-6

7 January 2021

Pathological findings in Gaucher disease type 2 patients following enzyme therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2898%2990023-6

7 January 2021

Prospective study of neurological responses to treatment with macrophage-targeted glucocerebrosidase in patients with type 3 Gaucher's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2898%2990023-6

7 January 2021

10.1016/S0268-960X(98)90023-6

Identifiers

DOI

1 reference

6 February 2018

PubMed ID

9661800

1 reference

6 February 2018